Steatotic liver disease in patients with chronic hepatitis C

Table 6 Comparison of responders and virologic non-responders, univariate analysis, median (Q1-Q3)/n (%)

Parameter	Responders (n = 656)	Non-responders (n = 13)	P value
Gender, women/men	339 (51.7)/317 (48.3)	1 (7.7) /12 (92.3)	0.0014
Age (years)	47 (36-63)	45 (42-52)	0.5863
Age ≥ 50	304 (46.3)	5 (38.5)	0.7802
BMI (kg/m2)	25.3 (22.7-28.4)	27.8 (25.1-32.4)	0.0250
ALT (IU/L)	55 (36-91)	77 (69-111)	0.0544
Albumin (g/dL)	4.1 (3.8-4.4)	3.3 (2.5-4)	0.0078
Bilirubin (mg/dL)	0.7 (0.5-0.9)	1.5 (1-2.3)	0.0000
Haemoglobin	14.4 (13.4-15.5)	14.4 (12.6-15.1)	0.3643
Platelets (× 1000/μL)	192 (145-234)	79 (74-158)	0.0001
Creatinine (mg/dL)	0.8 (0.7-0.9)	0.9 (0.8-1)	0.4954
INR	1.0 (1-1.1)	1.2 (1.1-1.4)	0.0001
HCV RNA (× 106 IU/mL)	1 (0.3-2.6)	0.6 (0.4-2.9)	0.7697
Current treatment regimen
SOF/VEL ± RBV	287 (43.7)	9 (69.2)	0.0900
GLE/PIB	364 (55.5)	4 (30.8)	0.0937
SOF/VEL/VOX	5 (0.8)	0	> 0.9999
Comorbidities
Any	504 (76.8)	10 (76.9)	> 0.9999
Hypertension	231 (35.2)	2 (15.4)	0.2376
Diabetes mellitus	66 (10.1)	2 (15.4)	0.6324
Obesity	112 (17.1)	4 (30.8)	0.2559
Autoimmune disorders	41 (6.3)	0	> 0.9999
Renal disease	56 (8.5)	1 (7.7)	> 0.9999
Non-HCC tumors	42 (6.4)	1 (7.7)	0.5818
Concomitant medications	401 (61.1)	11 (84.6)	0.0847
GT3	105 (16.0)	7 (53.8)	0.0022
History of previous therapy			0.0111
Treatment-naïve	611 (93.1)	9 (69.2)
Treatment-experienced	45 (6.9)	4 (30.8)
History of hepatic decompensation
Encephalopathy and/or ascites	19 (2.9)	5 (38.5)	< 0.0001
Ascites	17 (2.6)	5 (38.5)	< 0.0001
Encephalopathy	3 (0.5)	1 (7.7)	0.0756
Documented esophageal varices	41 (6.3)	7 (53.8)	< 0.0001
Hepatic decompensation at baseline
Encephalopathy and/or ascites	18 (2.7)	5 (38.5)	< 0.0001
Encephalopathy	7 (1.1)	1 (7.7)	0.1460
Ascites	17 (2.6)	4 (30.8)	0.0004
METAVIR F4	128 (19.5)	9 (69.2)	0.0002
CP B/C, in relation to F4	26 (20.3)	6 (46.2)	0.0026
HIV	1 (0.2)	0	> 0.9999
HBV (HBsAg+)	3 (0.5)	0	> 0.9999
HCC	8 (1.2)	1 (7.7)	0.1628
OLTx	0	0	NA

Q: Quartile; BMI: Body mass index; ALT: Alanine aminotransferase; INR: International normalized ratio; HCV: Hepatitis C virus; SOF/VEL ± RBV: Sofosbuvir/velpatasvir with or without ribavirin; GLE/PIB: Glecaprevir/pibrentasvir; SOF/VEL/VOX: Sofosbuvir/velpatasvir/voxilaprevir; HCC: Hepatocellular carcinoma; GT3: Genotype 3; F4: Fibrosis stage 4; CP B/C: Child-Pugh Class B or C; HIV: Human immunodeficiency virus; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; OLTx: Orthotopic liver transplantation.